TG Therapeutics raises funds for cancer combination drugTG Therapeutics provided one of the highlights of the American Society of Hematology (ASH) conference earlier this month Share XTG Therapeutics raises funds for cancer combination drughttps://pharmaphorum.com/news/tg-therapeutics-set-for-upsized-ipo-to-develop-cancer-combination-drug/
TG Therapeutics challenges Roche with FDA filing for CLL drugUS biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic Share XTG Therapeutics challenges Roche with FDA filing for CLL drughttps://pharmaphorum.com/news/tg-therapeutics-challenges-roche-with-fda-filing-for-cll-drug/
FDA to decide on TG Therapeutics’ lymphoma drug early next yearThe FDA has accepted TG Therapeutics’ filing for its lymphoma drug umbralisib, which if approved could compete against Share XFDA to decide on TG Therapeutics’ lymphoma drug early next yearhttps://pharmaphorum.com/news/fda-to-decide-on-tg-therapeutics-lymphoma-drug-early-next-year/
TG Therapeutics cancer trial setback sends shares tumblingTG Therapeutics (TG) has suffered a setback in its blood cancer drug trial, as the data available was Share XTG Therapeutics cancer trial setback sends shares tumblinghttps://pharmaphorum.com/news/tg-therapeutics-cancer-trial-setback-sends-shares-tumbling/
